A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

Chen, Li‐Tzong; Satoh, Taroh; Ryu, Min‐Hee; Chao, Yee; Kato, Ken; Cheol Chung, Hyun; Chen, Jen‐Shi; Muro, Kei; Ki Kang, Won; Yeh, Kun‐Huei; Yoshikawa, Takaki; Cheul Oh, Sang; Bai, Li-Yuan; Tamura, Takao; Lee, Keun‐Wook; Hamamoto, Yasuo; Gwang Kim, Jong; Chìn, Keisho; Oh, Do‐Youn; Minashi, Keiko; Choi, Y.; Tsuda, Masahiro; Sameshima, Hiroki; Kang, Yoon‐Koo; Boku, Narikazu

doi:10.1007/s10120-019-01034-7

Public

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

Published in Gastric Cancer • Dec 20, 2019

Authors:

Li‐Tzong Chen

Taroh Satoh

Min‐Hee Ryu

Abstract

BACKGROUND: Nivolumab showed improvement in overall survival (OS) in ATTRACTION-2, the first phase 3 study in patients with gastric/gastroesophageal junction (G/GEJ) cancer treated with ≥ 2 chemotherapy regimens. The 2-year follow-up results of ATTRACTION-2 are presented herein. METHODS: ATTRACTION-...

Subject

Nivolumab

Medicine

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!